22 October 2019 | By Victoria Rees (European Pharmaceutical Review)
The Joint Pharmaceutical Analysis Group held an event in London, discussing the testing of nitrosamine mutagenic impurities in pharmaceutical products and the next steps for manufacturers to take.
